These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6539880)

  • 1. Pergolide in the treatment of Parkinson's disease.
    Mear JY; Barroche G; de Smet Y; Weber M; Lhermitte F; Agid Y
    Neurology; 1984 Jul; 34(7):983-6. PubMed ID: 6539880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind trial of pergolide for Parkinson's disease.
    Diamond SG; Markham CH; Treciokas LJ
    Neurology; 1985 Mar; 35(3):291-5. PubMed ID: 3883232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further studies with pergolide in Parkinson disease.
    Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E; Nelson J
    Neurology; 1982 Oct; 32(10):1181-4. PubMed ID: 6889703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term study of pergolide in Parkinson's disease.
    Jankovic J
    Neurology; 1985 Mar; 35(3):296-9. PubMed ID: 3974887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
    Jankovic J
    Neurology; 1983 Apr; 33(4):505-7. PubMed ID: 6339985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dystonia-Parkinson syndrome: differential effects of levodopa and dopamine agonists.
    Klawans HL; Paleologos N
    Clin Neuropharmacol; 1986; 9(3):298-302. PubMed ID: 3719575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.
    Askenasy JJ; Yahr MD
    Neurology; 1985 Apr; 35(4):527-32. PubMed ID: 3982638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pergolide and bromocriptine therapy in parkinsonism.
    LeWitt PA; Ward CD; Larsen TA; Raphaelson MI; Newman RP; Foster N; Dambrosia JM; Calne DB
    Neurology; 1983 Aug; 33(8):1009-14. PubMed ID: 6348585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of pergolide and mesulergine.
    Lieberman AN; Gopinathan G; Neophytides A
    Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced Parkinson disease with pergolide.
    Lieberman A; Goldstein M; Leibowitz M; Neophytides A; Kupersmith M; Pact V; Kleinberg D
    Neurology; 1981 Jun; 31(6):675-82. PubMed ID: 7195484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with pergolide: decreased efficacy with time.
    Lieberman AN; Goldstein M; Leibowitz M; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R
    Neurology; 1984 Feb; 34(2):223-6. PubMed ID: 6538014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1985; 8(3):260-5. PubMed ID: 3899352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease with pergolide: a double-blind study.
    Ahlskog JE; Muenter MD
    Mayo Clin Proc; 1988 Oct; 63(10):969-78. PubMed ID: 3050300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study of pergolide in Parkinson's disease].
    Gonce M; Delwaide PJ
    Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is stereotactic surgical treatment still necessary for Parkinson's disease in the contemporary trend of medical therapy with dopamine receptor agonist?
    Amano K; Takakura K
    Stereotact Funct Neurosurg; 1997; 69(1-4 Pt 2):5-18. PubMed ID: 9711730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pergolide therapy for Parkinson's disease: neurobehavioral changes.
    Stern Y; Mayeux R; Ilson J; Fahn S; Cote L
    Neurology; 1984 Feb; 34(2):201-4. PubMed ID: 6538009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
    Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
    Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pergolide mesylate and idiopathic Parkinson disease.
    Tanner CM; Goetz CG; Glantz RH; Glatt SL; Klawans HL
    Neurology; 1982 Oct; 32(10):1175-9. PubMed ID: 6889702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
    Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.